Want to see IN:SUVEN full AI Analyst Report?
Top Page
Suven Life Sciences Limited
(SUVEN)
Select Model
Select Model
Rating:43Neutral
Price Target:
₹278.00
▲(68.48% Upside)
Action:Reiterated
Date:10/10/26
The score is weighed down primarily by weak financial performance—recurring losses, deteriorating margins, and ongoing cash burn—despite low leverage. Technicals are also negative (below key moving averages and negative MACD), with oversold indicators offering only limited support. Valuation provides little comfort given the negative P/E and lack of dividend yield data.
Positive Factors
FY2026 Revenue Growth
The FY2026 revenue rebound indicates that demand for the company’s offerings can recover after weaker periods. If the improvement is sustained, greater project activity and customer orders could provide a larger base from which operating efficiency and future profitability may develop.
Negative Factors
Persistent Unprofitability
Recurring operating and net losses show that the current business model is not converting activity into sustainable earnings. Continued unprofitability can restrict internal reinvestment, weaken capital productivity, and make future growth dependent on an eventual improvement in economics or external funding.
Read all positive and negative factors
Positive Factors
Negative Factors
FY2026 Revenue Growth
The FY2026 revenue rebound indicates that demand for the company’s offerings can recover after weaker periods. If the improvement is sustained, greater project activity and customer orders could provide a larger base from which operating efficiency and future profitability may develop.
Read all positive factors
Suven Life Sciences Limited (SUVEN) vs. iShares MSCI India ETF (INDA)
Market Cap
₹80.22B
Dividend Yield11.14%
Average Volume (3M)38.56K
Price to Earnings (P/E)―
Beta (1Y)1.84
Revenue Growth17.26%
EPS Growth-68.16%
CountryIN
Employees141
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-12.41
Shares Outstanding282,562,680
10 Day Avg. Volume33,009
30 Day Avg. Volume38,558
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)5.07
Price to Sales (P/S)421.72
P/FCF Ratio-9.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Suven Life Sciences Limited Business Overview & Revenue Model
Company Description
Suven Life Sciences Limited operates as a clinical-stage biopharmaceutical enterprise dedicated to the identification, progression, and commercialization of innovative therapeutic solutions. Its primary focus lies in addressing neurodegenerative c...
How the Company Makes Money
Suven Life Sciences has primarily generated revenue through business-to-business pharma services rather than branded drug sales. Key revenue streams have included: (1) Contract research and development services—fees for medicinal chemistry, proces...
Suven Life Sciences Limited Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
62
Positive
Cash Flow
9
Very Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 71.15M | 66.56M | 116.93M | 135.39M | 118.44M |
| Gross Profit | -419.28M | -276.33M | 108.69M | 129.74M | -137.31M |
| EBITDA | -2.71B | -1.55B | -994.18M | -1.11B | -1.17B |
| Net Income | -2.76B | -1.61B | -1.05B | -1.18B | -1.22B |
Balance Sheet | |||||
| Total Assets | 6.24B | 1.35B | 2.85B | 3.89B | 1.08B |
| Cash, Cash Equivalents and Short-Term Investments | 5.18B | 600.05M | 2.40B | 2.31B | 504.36M |
| Total Debt | 166.94M | 0.00 | 7.10M | 16.05M | 32.09M |
| Total Liabilities | 328.14M | 251.97M | 148.62M | 135.91M | 118.89M |
| Stockholders Equity | 5.91B | 1.10B | 2.70B | 3.75B | 961.45M |
Cash Flow | |||||
| Free Cash Flow | -3.03B | -1.86B | -1.15B | -1.06B | -1.47B |
| Operating Cash Flow | -2.98B | -1.48B | -1.15B | -1.03B | -1.28B |
| Investing Cash Flow | -4.66B | 1.49B | 944.36M | -2.61B | -222.29M |
| Financing Cash Flow | 7.57B | -7.10M | -10.54M | 3.96B | 1.46B |
Suven Life Sciences Limited Technical Analysis
Negative
165.00
Price Trends
339.10
Negative
315.90
Negative
241.78
Positive
Market Momentum
-16.57
Positive
28.95
Positive
9.44
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SUVEN, the sentiment is Negative. The current price of 165 is below the 20-day moving average (MA) of 319.40, below the 50-day MA of 339.10, and below the 200-day MA of 241.78, indicating a neutral trend. The MACD of -16.57 indicates Positive momentum. The RSI at 28.95 is Positive, neither overbought nor oversold. The STOCH value of 9.44 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:SUVEN.
Suven Life Sciences Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | ₹2.46T | 81.86 | ― | 0.33% | 16.35% | 26.84% | |
67 Neutral | ₹261.21B | -81.83 | ― | 0.07% | 0.78% | -420.81% | |
66 Neutral | ₹261.11B | 52.07 | ― | 0.17% | 78.33% | 182.61% | |
60 Neutral | ₹1.11T | 100.59 | ― | 0.10% | 22.62% | 114.66% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
50 Neutral | ₹61.24B | 3.95 | ― | ― | 2855.80% | ― | |
43 Neutral | ₹80.22B | -19.59 | ― | 11.14% | 17.26% | -68.16% |
* General Sector Average
IN:SUVEN
Suven Life Sciences Limited
283.65
85.25
42.97%
IN:DIVISLAB
Divi's Laboratories Limited
9,029.85
2,485.15
37.97%
IN:LAURUSLABS
Laurus Labs Ltd.
2,036.00
1,162.04
132.96%
IN:NEULANDLAB
Neuland Laboratories Ltd.
20,200.35
4,099.81
25.46%
IN:PPLPHARMA
Piramal Pharma Limited
193.85
0.30
0.15%
IN:SPARC
Sun Pharma Advanced Research Co. Ltd.
191.75
60.70
46.32%
Suven Life Sciences Limited Corporate Events
Suven Life Sciences completes enrollment in global Phase 3 Masupirdine trial for Alzheimer’s agitation
Sep 3, 2026
Suven Life Sciences has completed patient enrollment in its global Phase 3 trial of Masupirdine for agitation associated with Alzheimer’s dementia, exceeding its original target by randomizing 424 patients across sites in the U.S. and Europe...
Suven Life Sciences Opens Special Window for Physical Share Transfer Requests
Jul 14, 2026
Suven Life Sciences Limited has published newspaper advertisements in Business Standard and Nava Telangana announcing a special window for re-lodgment of transfer requests for physical share certificates. The move is in compliance with a recent SE...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.